CD274 and non-small cell lung carcinoma: Interestingly, when NSCLC patients were treated with typical ICIs like atezolizumab or nivolumab combined with paclitaxel and carboplatin, tumor PD-L1 expression tended to show no correlation with pathological response (34, 35).